Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.

No significant changes were observed in total muscle mass ( Figure 3F ), subcutaneous fat area, or visceral fat/subcutaneous fat ratio in either group, although visceral fat area showed a nonsignificant trend toward reduction in the empagliflozin group (P = 0.087).

also in 5,406 other papers